Table 2.
Leukemia-specific SIRs among patients with SCD, California, 1988-2014
| Observed cases | Expected cases | SIR | 95% CI | |
|---|---|---|---|---|
| Leukemia | 12 | 5.17 | 2.32 | (1.20-4.05) |
| Sex | ||||
| Male | 5 | 2.71 | 1.85 | (0.60-4.31) |
| Female | 7 | 2.47 | 2.84 | (1.14-5.84) |
| Age at diagnosis, y | ||||
| Pediatric, <15 | 1 | 1.47 | 0.68 | (0.02-3.79) |
| AYA, 15-39 | 6 | 1.78 | 3.37 | (1.24-7.33) |
| Adult, ≥40 | 5 | 1.92 | 2.60 | (0.84-6.07) |
| SCD severity* | ||||
| Less severe | 4 | 2.59 | 1.54 | (0.42-3.95) |
| Severe | 8 | 1.81 | 4.41 | (1.91-8.70) |
| Treatment era† | ||||
| 1988-1999 | 5 | 1.92 | 2.61 | (0.85-6.08) |
| 2000-2014 | 7 | 3.26 | 2.15 | (0.86-4.43) |
AYA, adolescent and young adult.
*
Patients with an average of ≥3 visits per year were defined as severe SCD; patients with an average <3 visits per year were defined as less severe SCD.17
†
Hydroxyurea was approved by the FDA in February 1998.